Antengene licenses ATG-106 to K2 Therapeutics for $20M upfront



[
Antengene licenses ATG-106 to K2 Therapeutics for $20M upfront
[og_img]
https://www.investing.com/news/company-news/antengene-licenses-atg106-to-k2-therapeutics-for-20m-upfront-93CH-4751700


Investing.com

Latest articles

spot_imgspot_img

Related articles

Leave a reply

Please enter your comment!
Please enter your name here

spot_imgspot_img